General Information of This Peptide-drug Conjugate (PDC)
PDC ID
PDC_00352
PDC Name
Tubugi-1-NPY
PDC Status
Investigative
Indication
In total 1 Indication(s)
Tumor
Structure
Peptide Name
[K4(C-βA-),F7,L17,P34]-hNPY
 Peptide Info 
Receptor Name
Neuropeptide Y receptor type 1 (NPY1R)
 Receptor Info 
Drug Name
Tubugis
 Drug Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
Disulfide bond
 Linker Info 
Peptide Modified Type
The modification of binding with chemical macromolecules
Formula
C246H367N61O65S3
#Ro5 Violations (Lipinski): 5 Molecular Weight 5315.205
Lipid-water partition coefficient (xlogp) -9.6816
Hydrogen Bond Donor Count (hbonddonor) 62
Hydrogen Bond Acceptor Count (hbondacc) 71
Rotatable Bond Count (rotbonds) 170
Full List of Activity Data of This Peptide-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 11 Activity Data Related to This Level
Experiment 1 Reporting the Activity Data of This PDC [1]
Indication Tumor
Efficacy Data Cell viability
0%
Administration Time 72 h
Administration Dosage 10 µM
Description
The 72 h treatment is more effective than the 6 h pulse treatment. Notably, in vitro antitumor activities of 8 were found to correlate very good with the hY1R expression levels, as detected by gene expression analyses using RT-qPCR. Both the cytotoxic activity and the hY1R expression level rank in the order SK-N-MC > MDA-MB-468 > MDA-MB-231 > 184B5, what proofs the hY1R-specific and -selective nature of the mode of antitumor action of the designed PDC 8. Importantly, the activity of 8 against the selected normal breast cell line 184B5 is in the same order of magnitude as for the hY1R-deficient tumor cell line (MDA-MB-231), both tested at even higher concentration of the PDC than for the Y1 cell lines.

   Click to Show/Hide
In Vitro Model Askin tumor SK-N-MC cell CVCL_0530
Experiment 2 Reporting the Activity Data of This PDC [1]
Indication Tumor
Efficacy Data Cell viability
2%
Administration Time 6 h
Administration Dosage 10 µM
Description
The 72 h treatment is more effective than the 6 h pulse treatment. Notably, in vitro antitumor activities of 8 were found to correlate very good with the hY1R expression levels, as detected by gene expression analyses using RT-qPCR. Both the cytotoxic activity and the hY1R expression level rank in the order SK-N-MC > MDA-MB-468 > MDA-MB-231 > 184B5, what proofs the hY1R-specific and -selective nature of the mode of antitumor action of the designed PDC 8. Importantly, the activity of 8 against the selected normal breast cell line 184B5 is in the same order of magnitude as for the hY1R-deficient tumor cell line (MDA-MB-231), both tested at even higher concentration of the PDC than for the Y1 cell lines.

   Click to Show/Hide
In Vitro Model Askin tumor SK-N-MC cell CVCL_0530
Experiment 3 Reporting the Activity Data of This PDC [1]
Indication Tumor
Efficacy Data Cell viability
5%
Administration Time 72 h
Administration Dosage 10 µM
Description
The 72 h treatment is more effective than the 6 h pulse treatment. Notably, in vitro antitumor activities of 8 were found to correlate very good with the hY1R expression levels, as detected by gene expression analyses using RT-qPCR. Both the cytotoxic activity and the hY1R expression level rank in the order SK-N-MC > MDA-MB-468 > MDA-MB-231 > 184B5, what proofs the hY1R-specific and -selective nature of the mode of antitumor action of the designed PDC 8. Importantly, the activity of 8 against the selected normal breast cell line 184B5 is in the same order of magnitude as for the hY1R-deficient tumor cell line (MDA-MB-231), both tested at even higher concentration of the PDC than for the Y1 cell lines.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma MDA-MB-468 cell CVCL_0419
Experiment 4 Reporting the Activity Data of This PDC [1]
Indication Tumor
Efficacy Data Cell viability
10%
Administration Time 6 h
Administration Dosage 10 µM
Description
The 72 h treatment is more effective than the 6 h pulse treatment. Notably, in vitro antitumor activities of 8 were found to correlate very good with the hY1R expression levels, as detected by gene expression analyses using RT-qPCR. Both the cytotoxic activity and the hY1R expression level rank in the order SK-N-MC > MDA-MB-468 > MDA-MB-231 > 184B5, what proofs the hY1R-specific and -selective nature of the mode of antitumor action of the designed PDC 8. Importantly, the activity of 8 against the selected normal breast cell line 184B5 is in the same order of magnitude as for the hY1R-deficient tumor cell line (MDA-MB-231), both tested at even higher concentration of the PDC than for the Y1 cell lines.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma MDA-MB-468 cell CVCL_0419
Experiment 5 Reporting the Activity Data of This PDC [1]
Indication Tumor
Efficacy Data Cell viability
20%
Administration Time 72 h
Administration Dosage 10 µM
Description
The 72 h treatment is more effective than the 6 h pulse treatment. Notably, in vitro antitumor activities of 8 were found to correlate very good with the hY1R expression levels, as detected by gene expression analyses using RT-qPCR. Both the cytotoxic activity and the hY1R expression level rank in the order SK-N-MC > MDA-MB-468 > MDA-MB-231 > 184B5, what proofs the hY1R-specific and -selective nature of the mode of antitumor action of the designed PDC 8. Importantly, the activity of 8 against the selected normal breast cell line 184B5 is in the same order of magnitude as for the hY1R-deficient tumor cell line (MDA-MB-231), both tested at even higher concentration of the PDC than for the Y1 cell lines.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma MDA-MB-231 cell CVCL_0062
Experiment 6 Reporting the Activity Data of This PDC [1]
Indication Tumor
Efficacy Data Cell viability
20%
Administration Time 72 h
Administration Dosage 10 µM
Description
The 72 h treatment is more effective than the 6 h pulse treatment. Notably, in vitro antitumor activities of 8 were found to correlate very good with the hY1R expression levels, as detected by gene expression analyses using RT-qPCR. Both the cytotoxic activity and the hY1R expression level rank in the order SK-N-MC > MDA-MB-468 > MDA-MB-231 > 184B5, what proofs the hY1R-specific and -selective nature of the mode of antitumor action of the designed PDC 8. Importantly, the activity of 8 against the selected normal breast cell line 184B5 is in the same order of magnitude as for the hY1R-deficient tumor cell line (MDA-MB-231), both tested at even higher concentration of the PDC than for the Y1 cell lines.

   Click to Show/Hide
In Vitro Model Normal Normal mammary gland epithelium Homo sapiens
Experiment 7 Reporting the Activity Data of This PDC [1]
Indication Tumor
Efficacy Data Cell viability
35%
Administration Time 6 h
Administration Dosage 10 µM
Description
The 72 h treatment is more effective than the 6 h pulse treatment. Notably, in vitro antitumor activities of 8 were found to correlate very good with the hY1R expression levels, as detected by gene expression analyses using RT-qPCR. Both the cytotoxic activity and the hY1R expression level rank in the order SK-N-MC > MDA-MB-468 > MDA-MB-231 > 184B5, what proofs the hY1R-specific and -selective nature of the mode of antitumor action of the designed PDC 8. Importantly, the activity of 8 against the selected normal breast cell line 184B5 is in the same order of magnitude as for the hY1R-deficient tumor cell line (MDA-MB-231), both tested at even higher concentration of the PDC than for the Y1 cell lines.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma MDA-MB-231 cell CVCL_0062
Experiment 8 Reporting the Activity Data of This PDC [1]
Indication Tumor
Efficacy Data Cell viability
50%
Administration Time 6 h
Administration Dosage 10 µM
Description
The 72 h treatment is more effective than the 6 h pulse treatment. Notably, in vitro antitumor activities of 8 were found to correlate very good with the hY1R expression levels, as detected by gene expression analyses using RT-qPCR. Both the cytotoxic activity and the hY1R expression level rank in the order SK-N-MC > MDA-MB-468 > MDA-MB-231 > 184B5, what proofs the hY1R-specific and -selective nature of the mode of antitumor action of the designed PDC 8. Importantly, the activity of 8 against the selected normal breast cell line 184B5 is in the same order of magnitude as for the hY1R-deficient tumor cell line (MDA-MB-231), both tested at even higher concentration of the PDC than for the Y1 cell lines.

   Click to Show/Hide
In Vitro Model Normal Normal mammary gland epithelium Homo sapiens
Experiment 9 Reporting the Activity Data of This PDC [1]
Indication Tumor
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
205 ± 49 nM
Description
As shown in Table 1, the cytotoxic potency of the tubugi-1-SH was - in case of HT-29 and PC-3 - by factors 5 to 8 higher compared to the entire peptide-toxin conjugate 8. The only slight increase of cytotoxic activity of compound 9 compared to the complete conjugate 8 in Colo320 cells is most likely caused by a generally weak responsiveness of Colo320 cells towards tubugi-1-SH and the entire conjugate tubugi-1-SS-NPY. When compared with HT-29 and PC-3 cells, the IC50 value of tubugi-1-SH is by factor 10 higher in Colo320. Since the membrane passage of tubugi-1-SH is not depending on a NPY receptor, there have to be other explanations for the reduced cytotoxic impact of tubugi-1 and corresponding derivatives in Colo320, rather than the NPY Y1 receptor expression level.

   Click to Show/Hide
In Vitro Model Prostate carcinoma PC-3 cell CVCL_0035
Experiment 10 Reporting the Activity Data of This PDC [1]
Indication Tumor
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
452 ± 60 nM
Description
As shown in Table 1, the cytotoxic potency of the tubugi-1-SH was - in case of HT-29 and PC-3 - by factors 5 to 8 higher compared to the entire peptide-toxin conjugate 8. The only slight increase of cytotoxic activity of compound 9 compared to the complete conjugate 8 in Colo320 cells is most likely caused by a generally weak responsiveness of Colo320 cells towards tubugi-1-SH and the entire conjugate tubugi-1-SS-NPY. When compared with HT-29 and PC-3 cells, the IC50 value of tubugi-1-SH is by factor 10 higher in Colo320. Since the membrane passage of tubugi-1-SH is not depending on a NPY receptor, there have to be other explanations for the reduced cytotoxic impact of tubugi-1 and corresponding derivatives in Colo320, rather than the NPY Y1 receptor expression level.

   Click to Show/Hide
In Vitro Model Colon cancer HT29 cell CVCL_A8EZ
Experiment 11 Reporting the Activity Data of This PDC [1]
Indication Tumor
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
706 ± 185 nM
Description
As shown in Table 1, the cytotoxic potency of the tubugi-1-SH was - in case of HT-29 and PC-3 - by factors 5 to 8 higher compared to the entire peptide-toxin conjugate 8. The only slight increase of cytotoxic activity of compound 9 compared to the complete conjugate 8 in Colo320 cells is most likely caused by a generally weak responsiveness of Colo320 cells towards tubugi-1-SH and the entire conjugate tubugi-1-SS-NPY. When compared with HT-29 and PC-3 cells, the IC50 value of tubugi-1-SH is by factor 10 higher in Colo320. Since the membrane passage of tubugi-1-SH is not depending on a NPY receptor, there have to be other explanations for the reduced cytotoxic impact of tubugi-1 and corresponding derivatives in Colo320, rather than the NPY Y1 receptor expression level.

   Click to Show/Hide
In Vitro Model Colon adenocarcinoma COLO 320 cell CVCL_1989
References
Ref 1 Synthesis of a tubugi-1-toxin conjugate by a modulizable disulfide linker system with a neuropeptide Y analogue showing selectivity for hY1R-overexpressing tumor cells. Beilstein J Org Chem. 2019 Jan 10;15:96-105. doi: 10.3762/bjoc.15.11. eCollection 2019.